Lenalidomide, rituximab (R2), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma

被引：0

作者：

Hill, Brian T. ^{[1
]}

Chen, Yanwen ^{[2
]}

Jagadeesh, Deepa ^{[1
]}

Dean, Robert ^{[1
]}

Koc, Omer ^{[1
]}

Boughan, Kirsten ^{[3
]}

Cooper, Brenda ^{[3
]}

Pohlman, Brad ^{[1
]}

Caimi, Paolo ^{[1
]}

Smith, Mitchell R. ^{[1
,4
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA

[2] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA

[3] Case Western Reserve Univ, Univ Hosp, Sch Med, Cleveland, OH USA

[4] Follicular Lymphoma Fdn, Washington, DC USA

来源：

LEUKEMIA & LYMPHOMA | 2024年 / 65卷 / 06期

关键词：

Rituximab; lenalidomide; ixazomib; follicular lymphoma; indolent lymphoma; PLUS RITUXIMAB; TRIAL; CELL;

D O I：

10.1080/10428194.2024.2325636

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lenalidomide and rituximab (R-2) is an effective frontline treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the safety and efficacy of addition of the proteasome inhibitor ixazomib to R-2 for treatment of iNHL through a phase I/II clinical trial for high-risk patients. Twenty patients were enrolled, 18 were treated. The target dose of ixazomib 4 mg weekly was achieved during dose escalation. The most common treatment-related adverse events (AEs) were low grade gastrointestinal, rash, neuropathy, and myalgia/arthralgia. There were 33% grade 2 and 17% grade 3 infections. With median follow-up of 5.2 years, four patients discontinued treatment due to lymphoma progression. Best overall response rate (ORR) was 61.2% [55.6% CR, 5.6% PR): 22.2% had stable disease and 16.7% had disease progression. Kaplan-Meier estimates of progression free and overall survival (OS) were 73% and 87% at 36 months, respectively. R-2 can safely be combined with ixazomib for treatment-na & iuml;ve iNHL patients.

引用

页码：768 / 773

页数：6

共 15 条

[1] Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups [J].

Batlevi, Connie L. ;

Sha, Fushen ;

Alperovich, Anna ;

Ni, Ai ;

Smith, Katy ;

Ying, Zhitao ;

Soumerai, Jacob D. ;

Caron, Philip C. ;

Falchi, Lorenzo ;

Hamilton, Audrey ;

Hamlin, Paul A. ;

Horwitz, Steven M. ;

Joffe, Erel ;

Kumar, Anita ;

Matasar, Matthew J. ;

Moskowitz, Alison J. ;

Moskowitz, Craig H. ;

Noy, Ariela ;

Owens, Colette ;

Palomba, Lia M. ;

Straus, David ;

von Keudell, Gottfried ;

Zelenetz, Andrew D. ;

Seshan, Venkatraman E. ;

Younes, Anas .

BLOOD CANCER JOURNAL, 2020, 10 (07)

[2] Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance) [J].

Blum, Kristie A. ;

Polley, Mei-Yin ;

Jung, Sin-Ho ;

Dockter, Travis J. ;

Anderson, Sarah ;

Hsi, Eric D. ;

Wagner-Johnston, Nina ;

Christian, Beth ;

Atkins, Jim ;

Cheson, Bruce D. ;

Leonard, John P. ;

Bartlett, Nancy L. .

CANCER, 2019, 125 (19) :3378-3389

[3] Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas [J].

Chong, Elise A. ;

Ahmadi, Tahamtan ;

Aqui, Nicole A. ;

Svoboda, Jakub ;

Nasta, Sunita D. ;

Mato, Anthony R. ;

Walsh, Kristy M. ;

Schuster, Stephen J. .

CLINICAL CANCER RESEARCH, 2015, 21 (08) :1835-1842

[4] A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 [J].

Evens, Andrew M. ;

Hong, Fangxin ;

Habermann, Thomas M. ;

Advani, Ranjana H. ;

Gascoyne, Randy D. ;

Witzig, Thomas E. ;

Quon, Andrew ;

Ranheim, Erik A. ;

Ansell, Stephen M. ;

Cheema, Puneet Singh ;

Dy, Philip A. ;

O'Brien, Timothy E. ;

Winter, Jane N. ;

Cescon, Terrence P. ;

Chang, Julie E. ;

Kahl, Brad S. .

CLINICAL CANCER RESEARCH, 2020, 26 (17) :4468-4477

[5] Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project [J].

Federico, Massimo ;

Bellei, Monica ;

Marcheselli, Luigi ;

Luminari, Stefano ;

Lopez-Guillermo, Armando ;

Vitolo, Umberto ;

Pro, Barbara ;

Pileri, Stefano ;

Pulsoni, Alessandro ;

Soubeyran, Pierre ;

Cortelazzo, Sergio ;

Martinelli, Giovanni ;

Martelli, Maurizio ;

Rigacci, Luigi ;

Arcaini, Luca ;

Di Raimondo, Francesco ;

Merli, Francesco ;

Sabattini, Elena ;

McLaughlin, Peter ;

Solal-Celigny, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4555-4562

[6] First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study [J].

Flinn, Ian W. ;

van der Jagt, Richard ;

Kahl, Brad ;

Wood, Peter ;

Hawkins, Tim ;

MacDonald, David ;

Simpson, David ;

Kolibaba, Kathryn ;

Issa, Samar ;

Chang, Julie ;

Trotman, Judith ;

Hallman, Doreen ;

Chen, Ling ;

Burke, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (12) :984-+

[7] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma [J].

Leonard, John P. ;

Trneny, Marek ;

Izutsu, Koji ;

Fowler, Nathan H. ;

Hong, Xiaonan ;

Zhu, Jun ;

Zhang, Huilai ;

Offner, Fritz ;

Scheliga, Adriana ;

Nowakowski, Grzegorz S. ;

Pinto, Antonio ;

Re, Francesca ;

Fogliatto, Laura Maria ;

Scheinberg, Phillip ;

Flinn, Ian W. ;

Moreira, Claudia ;

Cabecadas, Jose ;

Liu, David ;

Kalambakas, Stacey ;

Fustier, Pierre ;

Wu, Chengqing ;

Gribben, John G. ;

Calaminici, Maria ;

Copie-Bergman, Christiane ;

Lopez-Guillermo, Armando ;

O'Connor, Owen ;

Williams, Michael ;

Suciu, Stefan ;

Levine, Benjamin ;

Kern, Julie .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) :1188-+

[8] Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) [J].

Leonard, John P. ;

Jung, Sin-Ho ;

Johnson, Jeffrey ;

Pitcher, Brandelyn N. ;

Bartlett, Nancy L. ;

Blum, Kristie A. ;

Czuczman, Myron ;

Giguere, Jeffrey K. ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3635-+

[9] Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma [J].

Morschhauser, F. ;

Fowler, N. H. ;

Feugier, P. ;

Bouabdallah, R. ;

Tilly, H. ;

Palomba, M. L. ;

Fruchart, C. ;

Libby, E. N. ;

Casasnovas, R-O. ;

Flinn, I. W. ;

Haioun, C. ;

Maisonneuve, H. ;

Ysebaert, L. ;

Bartlett, N. L. ;

Bouabdallah, K. ;

Brice, P. ;

Ribrag, V. ;

Daguindau, N. ;

Le Gouill, S. ;

Pica, G. M. ;

Martin Garcia-Sancho, A. ;

Lopez-Guillermo, A. ;

Larouche, J-F. ;

Ando, K. ;

Gomes da Silva, M. ;

Andre, M. ;

Zachee, P. ;

Sehn, L. H. ;

Tobinai, K. ;

Cartron, G. ;

Liu, D. ;

Wang, J. ;

Xerri, L. ;

Salles, G. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10) :934-947

[10] Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era [J].

Nastoupil, Loretta J. ;

Sinha, Rajni ;

Byrtek, Michelle ;

Ziemiecki, Ryan ;

Zhou, Xiaolei ;

Taylor, Michael ;

Friedberg, Jonathan W. ;

Link, Brian K. ;

Cerhan, James R. ;

Dawson, Keith ;

Flowers, Christopher R. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) :724-734

← 1 2 →